![]() |
|
|
Vol. 283, Issue 2, 566-573, 1997
CNS Research Department, Synthélabo Recherche, Bagneux,
France
The ability of tiapride, a selective D2/D3
dopamine receptor antagonist, to exert discriminative stimulus control
of responding was investigated by training rats to discriminate this
drug (30 mg/kg) from saline in a two-lever, food-reinforcement
procedure. Acquisition of tiapride discrimination required a relatively
lengthy training period (mean of 76 sessions) but stable performance
was maintained throughout the 18- month study. The dose of tiapride eliciting 50% tiapride-lever choice (ED50) was 2.2 mg/kg.
After determination of the dose-effect curve with tiapride,
substitution tests with several dopamine antagonists and other
reference compounds were performed. All dopamine antagonists, including
amisulpride (ED50 4 mg/kg), sulpiride (18 mg/kg),
sultopride (1.5 mg/kg), clebopride (0.13 mg/kg), raclopride (0.16 mg/kg), metoclopramide (1.4 mg/kg), remoxipride (4.8 mg/kg), pimozide
(2.7 mg/kg), thioridazine (3.4 mg/kg), olanzapine (0.97 mg/kg),
chlorpromazine (1.9 mg/kg), risperidone (0.22 mg/kg) and haloperidol
(0.14 mg/kg), except clozapine (>10 mg/kg), produced dose-dependent
substitution for tiapride. Tiapride-like stimulus effects were observed
at doses that decreased response rates. However, ED50
values for substitution by tiapride, amisulpride, sulpiride,
sultopride, pimozide, clebopride and thioridazine were lower than
ED50 values for decreasing responding. Additional studies
were conducted to evaluate the ability of direct and indirect dopamine
agonists to attenuate the tiapride discriminative stimulus.
Pretreatment with d-amphetamine and nomifensine antagonized the
discriminative stimulus effects of tiapride. Quinpirole, 7-OH-DPAT, bromocriptine and apomorphine partially blocked the stimulus effects of
tiapride whereas SKF 38393 did not affect the discrimination. These
results from substitution and antagonism tests indicated that the
discriminative effects of tiapride are mediated by activity at
D2/D3 dopamine receptors.
This article has been cited by other articles:
![]() |
C. Cohen, O. E. Bergis, F. Galli, A. W. Lochead, S. Jegham, B. Biton, J. Leonardon, P. Avenet, F. Sgard, F. Besnard, et al. SSR591813, a Novel Selective and Partial {alpha}4{beta}2 Nicotinic Receptor Agonist with Potential as an Aid to Smoking Cessation J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 407 - 420. [Abstract] [Full Text] [PDF] |
||||